Mozambican Researcher Develops Promising Vaccine Against Pancreatic Cancer

A former student of Eduardo Mondlane University (UEM), Amade Sambo, is generating international attention by developing a potential vaccine against pancreatic cancer, one of the most aggressive and lethal forms of cancer. The research, which shows promising results in pre-clinical trials, was conducted by Sambo as part of his master's degree in Chemistry at the prestigious Osaka University in Japan.

Chemically synthesized, the vaccine has demonstrated an effective immune response even at minimal doses. According to the researcher, the formula includes a self-adjuvant component, which significantly reduces the side effects usually associated with this type of therapy. "The vaccine proved to be robust, with improved specificity and great potential to advance to clinical trials," explained Sambo.

 This scientific project, which could represent a historic milestone for Mozambican science, is now preparing for the clinical testing phase. However, this process is lengthy and could take between five and ten years, depending on the effectiveness demonstrated at each stage. Taking advantage of the visibility of his work, the researcher appealed for greater investment in scientific research in Mozambique, emphasizing that the country has the talent and capacity to contribute to global health solutions.

 With a final average of 96% in his master's degree—equivalent to 19 out of 20 in the Mozambican system—Amade Sambo now plans to publish scientific articles based on the results obtained. The goal is not only to broaden the impact of his work, but also to facilitate a wider understanding of his discovery by the international scientific community.